Otonomy Inc

NASDAQ:OTIC  
2.07
-0.03 (-1.43%)
Regulatory, Other Pre-Announcement

Otonomy Reports Positive Top-Line Results From Phase 1/2 Clinical Trial Of OTO-413 In Patients With Hearing Loss

Published: 12/17/2020 12:22 GMT
Otonomy Inc (OTIC) - Otonomy Reports Positive Top-line Results From Phase 1/2 Clinical Trial of Oto-413 in Patients With Hearing Loss.
Otonomy Inc - Intends to Continue Clinical Development of Oto-413.
Otonomy - Continue to Look Forward to 3rd Clinical Catalyst With Results From Phase 3 Trial of Otividex in MÉniÈre's Disease Still Expected in Q1 2021.